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INTRODUCTION
Neuroendocrine tumours of the pancreas have
an annual incidence of approximately per 100,000
population. Up to 85% ofthese tumours secrete pepti-
des, many of which cause characteristic clinical
syndromes. While pancreatic neuroendocrine tumours
frequently express immunoreactivity for multiple
peptides, they rarely produce more than one clinical
syndrome due to excess peptide secretion. We report
two patients with pancreatic neuroendocrine
neoplasia in each of whom there were characteristic
clinical features due to hypersecretion oftwo bioactive
peptides.
CASE NO: 1
A 41-year-old man with recently diagnosed sarcoi-
dosis underwent cholecystectomy for gallstones
in 1986. At operation he was found to have
multiple metastatic lesions throughout the liver
with no identifiable primary site; histological examina-
tion showed neuroendocrine tumour. A gut hormone
screen at that time was normal, but postoperative CT
scan demonstrated a lesion in the tail of pancreas.
Thereafter he attended a homeopathy clinic and de-
clined conventional medical treatment.
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In July 1990 he developed symptomatic hypercal-
caemia (4.5 mmol/1, normal 2.1-2.6 mmol/1), which
was treated with forced diuresis, calcitonin and bi-
phosphonates. Serum parathyroid hormone was
undetectable, but parathyroid hormone-related pro-
tein (PTHRP) was elevated at 7.8 pmol/1
(normal < 0.5 pmol/1). Somatostatin was also
markedly elevated at 774pmo 1/1 (normal < 100pmo 1/
1); vasoactive intestinal peptide, pancreatic poly-
peptide, gastrin, glucagon, and neurotensin levels
were all normal. Hepatic artery embolisation reduced
the PTHRP level to 6.1 pmol/1, and at a second
embolisation the splenic artery and an accessory artery
to the left liver from the left gastric artery were oc-
cluded; thereafter serum calcium returned to normal.
In December 1990 he was noted to be mildly diabetic
and was started on glibenclamide.
In October 1991 the patient returned with severe
hypercalcaemia (4.1 mmol/1) and was transferred
to this unit for surgical debulking of his tumour.
At operation a 20 cm tumour was found arising
from the body and tail of the pancreas involving
the left kidney and splenic flexure ofcolon. An en bloc
distal pancreatectomy, splenectomy, left nephrec-
tomy and left hemicolectomy was performed,
from which he made an uncomplicated recovery.
By the seventh postoperative day the serum calcium
was 2.7 mmol/1 and PTHRP was 1.1 pmol/1;
however somatostatin remained elevated at 1141
pmol/1. Histological examination of tumour tissue
showed typical features of a pancreatic neuroendo-
crine tumour with nests of polygonal cells and a focal
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trabecular pattern. Vascular invasion and lymph node
involvement were noted. Immunohistochemical stain-
ing of the resected tumour was positive for neuron
specific enolase, chromogranin and somatostatin
and was negative for pancreatic polypeptide, insulin,
and VIP.
In February 1992 he was readmitted to hospital
with severe hypercalcaemia associated with seizures.
His general condition deteriorated and he died within
three weeks.
CASE NO: 2
A 68-year-old man presented with a long history of
recurrent peptic ulceration. He had undergone truncal
vagotomy and pyloroplasty in 1982, antrectomy in
1983 and subtotal gastrectomy in 1986. In 1987 his
gastrin level was 257 pmol/1 (normal < 40 pmol/1)
indicating that he had Zollinger-Ellison syndrome.
Ultrasound and CT scanning failed to localise a
gastrinoma, and his symptoms were controlled
with omeprazole. In April 1991, he began to experi-
ence symptoms ofsevere hypoglycaemia.A supervised
fast in hospital precipitated hypoglycaemia with
inappropriate hyperinsulinism (glucose < 2.0mmo 1/1;
insulin 119 mU/1, reference range 3-20 mU/1; C-
peptide 1214 pmol/1). Serum gastrin was 308 pmol/1.
CT scan now showed a 14 x 18 cm tumour in the tail
of pancreas with at least one liver metastasis, and
visceral angiography confirmed multiple hepatic
metastases. Distal pancreatectomy and splenectomy
was performed together with enucleation of four
liver metastases, thereby removing all macroscopic
disease. Postoperative gastrin level was 4 pmol/1.
During a 24 hour fast the blood glucose remained
above 5.6 mmol/1. Histological examination showed
features typical of a neuroendocrine tumour.
Immuno-histochemical examination of the resected
tumour was positive for neuron Specific enolase,
chromogranin, insulin, C-peptide, gastrin and
somatostatin. Staining was negative for pancreatic
polypeptide and VIP.
He remains asymptomatic at 18 months, and CT
scan has shown no evidence of recurrent disease.
DISCUSSION
The clinical manifestation oftwo hormone syndromes
in pancreatic endocrine neoplasia has only been re-
ported with malignant tumours. In afive-year analysis
of the results from a supraregional assay service in the
U.K., Wynick and colleagues reported that 24 of 353
(6.8%) patients with functioning malignant tumours
developed a second hormone syndrome at a median
interval of 19 months after initial diagnosis 1. Themost
common presenting tumours in this group were
glucagonomas, followed by gastrinomas. The devel-
opment of a second peptide syndrome was associated
with marked clinical deterioration and death in over
90% of these patients.
Both our patients showed features of two clinical
syndromes. The first patient had gallstones and mild
diabetes, typical features ofthe somatostatinoma syn-
drome. He did not exhibit diarrhoea, the other typical
finding in this syndrome. He subsequently developed
severe hypercalcaemia due to secretion of PTHRP, a
recently described peptide that mimics the physiologi-
cal action of parathyroid hormone 2. PTHRP ex,
pression has been demonstrated in both normal ant
neoplastic islet cell tissue by Asa and colleagues
In our second patient, the intractable ulcer diathesis
and subsequent neuroglycopenic episodes were
clear consequences of first gastrin and then insuli
hypersecretion. Resection of the pancreatic tumour:
was associated with decreases in the serum levels oftht:
peptides responsible for the clinical syndromes in both
patients. Immunoreactivity for the relevant peptides
was confirmed in the excised tumours, with the excep-
tion of PTHRP for which immunohistochemical ex-
amination was not performed. Concomitant secretio
of insulin and gastrin has previously been reported it.
a small number of cases 4-6. In an extensive review of
the Zollinger-Ellison tumour registry, 2% of patients
also had insulin-secreting tumours 7. Production of
PTHRP in pancreatic neuroendocrine tumours in
sufficient quantity to cause symptomatic hypercalcae-
mia has been reported in a few patients 8,9, including
one patient in whom concomitant secretion of soma
tostatin and PTHRP was documented 10.
,Secretion ofmore than one peptide may occur as a
result of cellular dysdifferentiation. Small numbers of
proliferative cells, uncommitted to a particular differ-
entiation pathway, are present in normal islet tissue
and are increased in number in regenerating tissue. If
these cells undergo malignant transformation, they
may synthesize more than one biocative peptide in
sufficient amounts to cause clinical syndromes of
peptide excess.
Serum peptide levels should be regularly checked in
patients who are being treated for malignant pancre-
atic neuroendocrine tumours to detect development of
a second hormone syndrome. Recent improvements inDUAL HORMONE SYNDROMES IN PANCREATIC TUMOURS 263
survival of these patients because of advances in
chemotherapy and radiological and surgical interven-
tional techniques may make this a commoner clinical
scenario.
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